Ma A - Search Results

1

Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.

Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, Kurosugi A, Kogure T, Ma Y, Zhang J, Ogawa K, Kan M, Iwanaga T, Sakuma T, Kanayama K, Kanzaki H, Kojima R, Nakagawa R, Kondo T, Nakamoto S, Muroyama R, Kato J, Mimura N, Ma A, Jin J, Kato N. Qiang N, et al. Among authors: ma a, ma y. Int Immunopharmacol. 2023 May;118:110068. doi: 10.1016/j.intimp.2023.110068. Epub 2023 Mar 29. Int Immunopharmacol. 2023. PMID: 37001386

2

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.

Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, Zheng D, Jin J, Wang GG. Xu B, et al. Among authors: ma a. Blood. 2015 Jan 8;125(2):346-57. doi: 10.1182/blood-2014-06-581082. Epub 2014 Nov 13. Blood. 2015. PMID: 25395428 Free PMC article.

3

EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.

Katona BW, Liu Y, Ma A, Jin J, Hua X. Katona BW, et al. Among authors: ma a. Cancer Biol Ther. 2014;15(12):1677-87. doi: 10.4161/15384047.2014.972776. Cancer Biol Ther. 2014. PMID: 25535899 Free PMC article.

4

Structure-activity relationship studies of SETD8 inhibitors.

Ma A, Yu W, Xiong Y, Butler KV, Brown PJ, Jin J. Ma A, et al. Medchemcomm. 2014 Dec;5(12):1892-1898. doi: 10.1039/C4MD00317A. Medchemcomm. 2014. PMID: 25554733 Free PMC article.

5

Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.

Yang X, Li F, Konze KD, Meslamani J, Ma A, Brown PJ, Zhou MM, Arrowsmith CH, Kaniskan HÜ, Vedadi M, Jin J. Yang X, et al. Among authors: ma a. J Med Chem. 2016 Aug 25;59(16):7617-33. doi: 10.1021/acs.jmedchem.6b00855. Epub 2016 Aug 11. J Med Chem. 2016. PMID: 27468126 Free PMC article.

6

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.

Alzrigat M, Párraga AA, Agarwal P, Zureigat H, Österborg A, Nahi H, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H. Alzrigat M, et al. Among authors: ma a. Oncotarget. 2017 Feb 7;8(6):10213-10224. doi: 10.18632/oncotarget.14378. Oncotarget. 2017. PMID: 28052011 Free PMC article.

7

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.

Huang Q, He S, Tian Y, Gu Y, Chen P, Li C, Huang J, Liu Y, Yu H, Jin M, Hu S, Tong Q, Ma A, Jin J, Hexner E, Fung H, Reshef R, Zhang Y, Zhang Y. Huang Q, et al. Among authors: ma a. Blood. 2017 May 18;129(20):2737-2748. doi: 10.1182/blood-2016-08-735886. Epub 2017 Feb 28. Blood. 2017. PMID: 28246193 Free PMC article.

8

Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.

Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A. Rizq O, et al. Among authors: ma a. Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10. Clin Cancer Res. 2017. PMID: 28490465 Free PMC article.

9

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

Alzrigat M, Párraga AA, Majumder MM, Ma A, Jin J, Österborg A, Nahi H, Nilsson K, Heckman CA, Öberg F, Kalushkova A, Jernberg-Wiklund H. Alzrigat M, et al. Among authors: ma a. Oncotarget. 2017 Oct 20;8(61):103731-103743. doi: 10.18632/oncotarget.21909. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262596 Free PMC article.

10

Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.

Rizk M, Rizq O, Oshima M, Nakajima-Takagi Y, Koide S, Saraya A, Isshiki Y, Chiba T, Yamazaki S, Ma A, Jin J, Iwama A, Mimura N. Rizk M, et al. Among authors: ma a. Cancer Sci. 2019 Dec;110(12):3695-3707. doi: 10.1111/cas.14207. Epub 2019 Oct 22. Cancer Sci. 2019. PMID: 31571328 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,560 results

Search Page